Literature DB >> 24044790

Hypoxia imaging with [¹⁸F]HX4 PET in NSCLC patients: defining optimal imaging parameters.

Catharina M L Zegers1, Wouter van Elmpt, Roel Wierts, Bart Reymen, Hoda Sharifi, Michel C Öllers, Frank Hoebers, Esther G C Troost, Rinus Wanders, Angela van Baardwijk, Boudewijn Brans, Jonas Eriksson, Bert Windhorst, Felix M Mottaghy, Dirk De Ruysscher, Philippe Lambin.   

Abstract

BACKGROUND AND
PURPOSE: [(18)F]HX4 is a promising hypoxia PET-tracer. Uptake, spatio-temporal stability and optimal acquisition parameters for [(18)F]HX4 PET imaging were evaluated in non-small cell lung cancer (NSCLC) patients.
MATERIALS AND METHODS: [(18)F]HX4 PET/CT images of 15 NSCLC patients were acquired 2h and 4h after injection (p.i.). Maximum standardized-uptake-value (SUV(max)), tumor-to-blood-ratio (TBR(max)), hypoxic fraction (HF) and contrast-to-noise-ratio (CNR) were determined for all lesions. To evaluate spatio-temporal stability, DICE-similarity and Pearson correlation coefficients were calculated. Optimal acquisition-duration was assessed by comparing 30, 20, 10 and 5 min acquisitions.
RESULTS: Considerable uptake (TBR >1.4) was observed in 18/25 target lesions. TBR(max) increased significantly from 2 h (1.6 ± 0.3) to 4 h p.i. (2.0 ± 0.6). Uptake patterns at 2 h and 4 h p.i. showed a strong correlation (R=0.77 ± 0.10) with a DICE similarity coefficient of 0.69 ± 0.08 for the 30% highest uptake volume. Reducing acquisition-time resulted in significant changes in SUV(max) and CNR. TBR(max) and HF were only affected for scan-times of 5 min.
CONCLUSIONS: The majority of NSCLC lesions showed considerable [(18)F]HX4 uptake. The heterogeneous uptake pattern was stable between 2 h and 4 h p.i. [(18)F]HX4 PET imaging at 4 h p.i. is superior to 2 h p.i. to reach highest contrast. Acquisition time may be reduced to 10 min without significant effects on TBR(max) and HF.
Copyright © 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  HX4; Hypoxia; Imaging; NSCLC; PET

Mesh:

Substances:

Year:  2013        PMID: 24044790     DOI: 10.1016/j.radonc.2013.08.031

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  28 in total

Review 1.  Radiopharmaceuticals as probes to characterize tumour tissue.

Authors:  Israt S Alam; Mubarik A Arshad; Quang-Dé Nguyen; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

2.  Clostridium to treat cancer: dream or reality?

Authors:  Jan Theys; Philippe Lambin
Journal:  Ann Transl Med       Date:  2015-05

Review 3.  Molecular imaging of tumor hypoxia with positron emission tomography.

Authors:  Olivia J Kelada; David J Carlson
Journal:  Radiat Res       Date:  2014-03-27       Impact factor: 2.841

4.  In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.

Authors:  Catharina M L Zegers; Wouter van Elmpt; Bart Reymen; Aniek J G Even; Esther G C Troost; Michel C Ollers; Frank J P Hoebers; Ruud M A Houben; Jonas Eriksson; Albert D Windhorst; Felix M Mottaghy; Dirk De Ruysscher; Philippe Lambin
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

Review 5.  Molecular imaging of hypoxia in non-small-cell lung cancer.

Authors:  Connie Yip; Philip J Blower; Vicky Goh; David B Landau; Gary J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-21       Impact factor: 9.236

Review 6.  F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.

Authors:  Joseph G Rajendran; Kenneth A Krohn
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

Review 7.  Validation of functional imaging as a biomarker for radiation treatment response.

Authors:  C Jentsch; B Beuthien-Baumann; E G C Troost; G Shakirin
Journal:  Br J Radiol       Date:  2015-05-29       Impact factor: 3.039

Review 8.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 9.  PET in the management of locally advanced and metastatic NSCLC.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

10.  Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.

Authors:  Adriana Estrada-Bernal; Anh T Le; Andrea E Doak; Vijaya G Tirunagaru; Shevan Silva; Matthew R Bull; Jeff B Smaill; Adam V Patterson; Chul Kim; Stephen V Liu; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2020-12-22       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.